Table 2.
Characteristics of MRD-positive patients.
| Pt.# | Age | Cytogenetics (initial) | Dg. | Prior SCT | Rem. status | Flow cytometry | Cytogenetics | FISH | Type of transplant | Conditioning protocol/intensity | Relapse | aGVHD | cGVHD | TRM | Cause of death | OS |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 10 | 61 | Normal | AML | No | CR1 | 2–3% myeloblasts | ck | / | R 8/8 PBSC | NonTBI/Reduced intensity | +85 | 0 | Yes | No | L, G, OF | +138 |
| 11 | 62 | 46, xy, del(7)(p15)[23]/47,xy,+8[7] | sAML | No | CR1 | 1% coexpressing CD34+/CD117+mb | 47, xy,+8 | Abn. signal pattern, +8 | R 8/8 PBSC | TBI/Myeloablative | +102 | 4 | No | No | L | +196 |
| 12 | 45 | normal | AML | No | CR2 | 3.5% abn mb | 46, xx | Normal signal pattern | R 8/8 PBSC | TBI/Myeloablative | +210 | 1 | Yes | No | L, G | +299 |
| 14 | 48 | normal; FISHdel16p13 | AML | Auto SCT | CR2 | 4% myeloblasts | 46, xy, del16 (q23,q23) | Abn. signal pattern, del 16p | R 8/8 PBSC | NonTBI/Myeloablative | +88 | 4 | No | No | L, G | +96 |
| 21 | 43 | normal | AML | No | CR2 | 2% mb, 25–30% monocytes | 46, xy | / | R 8/8 PBSC | NonTBI/Reduced intensity | +245 | 1 | No | No | L | +370 |
| 22 | 50 | normal | AML | No | CR1 | 15–20% monocytes | 46, xy | / | R 8/8 PBSC | TBI/Myeloablative | No | 1 | No | +82 | I | +82 |
| 25 | 49 | normal | AML | Auto SCT | CR2 | <2% myeloblasts | ck | / | U 6/6 CB | NonTBI/Myeloablative | No | 0 | No | Alive | Alive | >+1512 |
| 28 | 46 | t(11q23, 17q25)/t(11,17) | sAML | No | CR1 | 1% myeloblasts | 46, xx | MLL gene rearrangement 11q23 | R 8/8 BM | TBI/Myeloablative | +260 | 3 | No | Alive | Alive | >+370 |
| 31 | 29 | unknown | AML | No | CR2 | 1% abn mb | 46, xy | / | R 8/8 PBSC | NonTBI/Myeloablative | +42 | 0 | No | No | L | +98 |
| 32 | 56 | ck | sAML | No | CR2 | / | ck | Abn. signal pattern, +9/del7q | R 8/8 BM | NonTBI/Reduced intensity | +110 | 1 | No | No | L | +126 |
| 35 | 61 | unknown | AML | Auto SCT | CR2 | 3% abn monocytic cells | 46, xx | / | U 7/8 BM | NonTBI/Reduced intensity | +179 | 2 | No | No | L | +184 |
| 39 | 45 | normal | AML | No | CR2 | 5% abn mb 10% CD34+/CD117+mb | 46, xx | / | U 5/6 CB | TBI/Myeloablative | No | 3 | No | Alive | Alive | >+1051 |
| 43 | 48 | ck | sAML | No | CR1 | 1% mb | ck | Abn. signal pattern 5q−, 7q− | U 4/6 CB | NonTBI/Myeloablative | +601 | 1 | No | No | L | +662 |
| 46 | 28 | del7q− | AML | No | CR1 | 10% CD34+/CD117+mb | 46, xx | Normal signal pattern | U 5/6CB | NonTBI/Reduced intensity | No | 0 | No | No | L | +269 |
| 50 | 41 | del5q,7q | sAML | No | CR1 | 4% abn.mb | / | / | U 8/8 PBSC | TBI/Myeloablative | +114 | 2 | No | No | L | +156 |
| 52 | 61 | normal | sAML | No | CR1 | Leukemia cutis | 46, xy | / | R 8/8 PBSC | TBI/Myeloablative | No | 4 | No | +86 | H, G | +86 |
| 53 | 52 | 47, xx,+8 | AML | No | CR1 | <2% mb | 46, xx | Abn. signal pattern, +8q | U 5/6 CB | TBI/Myeloablative | No | 2 | No | Alive | Alive | >+638 |
| 54 | 61 | FISH del7q | sAML | No | CR1 | 4% mb | 46, xy,+1, der (1,7) (q10;p10) | Abn. signal pattern 7q, +21q | R 8/8 PBSC | TBI/Myeloablative | No | 4 | No | +78 | I, G, OF | +78 |
| 58 | 65 | del20q | sAML | No | CR2 | 4% abn. mb | 46, xy, del (20) (q11.2q13.3) | / | U 8/8 BM | NonTBI/Myeloablative | No | 0 | Yes | +385 | G, OF | +385 |
Pt: patient; Dg: Diagnosis; Rem: status remission status; FISH: fluorescence in situ hybridization; aGVHD: acute graft-vs.-host disease; cGVHD: chronic graft-vs.-host disease; TRM: treatment related mortality; OS: overall survival; M: male; F: female; AML: acute myeloid leukemia; sAML: secondary acute myeloid leukemia; Auto SCT: autologous stem cell transplant; CR1: first complete remission; CR2: second complete remission; abn: abnormal; mb: myeloblasts; ck: complex karyotype; R: related; U: unrelated; PBSC: peripheral blood stem cells; BM: bone marrow; CB: cord blood; TBI: total body irradiation; non-TBI: non total body irradiation; L: leukemia; G: GVHD; I: infection; H: hemorrhage; OF: organ failure.